Kholoud Porter
Kholoud Porter
Verified email at
Cited by
Cited by
Changes in the risk of death after HIV seroconversion compared with mortality in the general population
K Bhaskaran, O Hamouda, M Sannes, F Boufassa, AM Johnson, ...
Jama 300 (1), 51-59, 2008
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy
MT May, M Gompels, V Delpech, K Porter, C Orkin, S Kegg, P Hay, ...
AIDS (London, England) 28 (8), 1193, 2014
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …
L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ...
The Lancet infectious diseases 11 (5), 363-371, 2011
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
M May, M Gompels, V Delpech, K Porter, F Post, M Johnson, D Dunn, ...
Bmj 343, 2011
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy
B Marin, R Thiébaut, HC Bucher, V Rondeau, D Costagliola, M Dorrucci, ...
AIDS (London, England) 23 (13), 1743, 2009
Changes in the incidence and predictors of human immunodeficiency virus–associated dementia in the era of highly active antiretroviral therapy
K Bhaskaran, C Mussini, A Antinori, AS Walker, M Dorrucci, C Sabin, ...
Annals of neurology 63 (2), 213-221, 2008
Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm3: Assessment of Need …
S Lodi, A Phillips, G Touloumi, R Geskus, L Meyer, R Thiébaut, ...
Clinical infectious diseases 53 (8), 817-825, 2011
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study
UK Group on Transmitted HIV Drug Resistance
Bmj 331 (7529), 1368, 2005
Beyond viral suppression of HIV–the new quality of life frontier
JV Lazarus, K Safreed-Harmon, SE Barton, D Costagliola, N Dedes, ...
BMC medicine 14 (1), 1-5, 2016
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007
JJ van der Helm, M Prins, J del Amo, HC Bucher, G Chêne, M Dorrucci, ...
Aids 25 (8), 1083-1091, 2011
Prospective study of clinical, laboratory, and ancillary staff with accidental exposures to blood or body fluids from patients infected with HIV.
M McEvoy, K Porter, P Mortimer, N Simmons, D Shanson
Br Med J (Clin Res Ed) 294 (6587), 1595-1597, 1987
Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion
S Lodi, M Guiguet, D Costagliola, M Fisher, A De Luca, K Porter, ...
Journal of the National Cancer Institute 102 (11), 784-792, 2010
Timing of HAART initiation and clinical outcomes among HIV-1 seroconverters
MJ Funk, JS Fusco, SR Cole, JC Thomas, K Porter, JS Kaufman, ...
Archives of internal medicine 171 (17), 1560, 2011
Long-term mortality in HIV-positive individuals virally suppressed for> 3 years with incomplete CD4 recovery
FN Engsig, R Zangerle, O Katsarou, F Dabis, P Reiss, J Gill, K Porter, ...
Clinical infectious diseases 58 (9), 1312-1321, 2014
Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS …
A Babiker, S Darby, D De Angelis, D Kwart, K Porter, V Beral, ...
Lancet 355 (9210), 2000
Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women
I Jarrin, R Geskus, K Bhaskaran, M Prins, S Perez-Hoyos, R Muga, ...
American journal of epidemiology 168 (5), 532-540, 2008
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion
S Lodi, L Meyer, AD Kelleher, M Rosinska, J Ghosn, M Sannes, K Porter
Archives of internal medicine 172 (16), 1252-1255, 2012
Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997
J van der Helm, R Geskus, C Sabin, L Meyer, J Del Amo, G Chêne, ...
Gastroenterology 144 (4), 751-760. e2, 2013
Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts
G Touloumi, N Pantazis, D Pillay, D Paraskevis, ML Chaix, HC Bucher, ...
Clinical infectious diseases 56 (6), 888-897, 2013
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003
B Masquelier, K Bhaskaran, D Pillay, R Gifford, E Balestre, LB Jørgensen, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 40 (5), 505-511, 2005
The system can't perform the operation now. Try again later.
Articles 1–20